PMID: Summary Keywords Crohns disease, GLP, GLP-1, GLP-2 receptor agonist, IBD - inflammatory bowel disease, ulcerative colitis Citation Lee JJ, Bajgain P and Lightner AL (2026) GLP-1 and GLP-2 as intestinal reparative therapies in inflammatory bowel disease: mechanisms, translation, and clinical opportunity
This hearing is critical, as the litigation depends on whether the plaintiffs experts can present sound scientific evidence linking GLP-1 drugs to the alleged injuries
Authors' contributions: JS and DF participated in the conception and design of the review, revised the whole manuscript, and read and approved the final manuscript
This multi-pathway approach helps explain why retatrutide's clinical effects exceed what would be predicted from simply adding the individual benefits of each receptor pathway